Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:BCT NASDAQ:IPA NASDAQ:SVA NASDAQ:TH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.19$0.43▼$3.25$96.68M0.532.11 million shs1.97 million shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.67M0.73N/AN/ATHTarget Hospitality$17.21+1.0%$15.84$5.97▼$18.93$1.72B1.47956,729 shs82,178 shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%IPAImmunoPrecise Antibodies0.00%0.00%0.00%0.00%+220.34%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%THTarget Hospitality+3.65%-0.12%-5.75%+75.67%+143.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.19$0.43▼$3.25$96.68M0.532.11 million shs1.97 million shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.67M0.73N/AN/ATHTarget Hospitality$17.21+1.0%$15.84$5.97▼$18.93$1.72B1.47956,729 shs82,178 shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%IPAImmunoPrecise Antibodies0.00%0.00%0.00%0.00%+220.34%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%THTarget Hospitality+3.65%-0.12%-5.75%+75.67%+143.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTBriaCell Therapeutics 0.00N/AN/AN/AIPAImmunoPrecise Antibodies 0.00N/AN/AN/ASVASinovac Biotech 0.00N/AN/AN/ATHTarget Hospitality 2.60Moderate Buy$19.3312.37% UpsideCurrent Analyst Ratings BreakdownLatest SVA, TH, BCT, and IPA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026THTarget Hospitality Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$22.005/13/2026THTarget Hospitality OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $21.004/9/2026THTarget Hospitality OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$11.00 ➝ $18.004/6/2026THTarget Hospitality Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.00 ➝ $15.003/27/2026THTarget Hospitality Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/17/2026THTarget Hospitality OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$11.003/12/2026THTarget Hospitality Texas CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/11/2026THTarget Hospitality Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.00(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTBriaCell TherapeuticsN/AN/AC$3.34 per share3.17C$3.60 per shareN/AIPAImmunoPrecise Antibodies$17.59M5.50N/AN/A$0.37 per share5.66SVASinovac Biotech$386.01M1.67$0.54 per share11.89$143.24 per share0.05THTarget Hospitality$320.64M5.37$0.42 per share41.21$3.90 per share4.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTBriaCell TherapeuticsN/A-C$0.38N/AN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%N/ASVASinovac Biotech-$59.68MN/AN/AN/AN/AN/AN/AN/A8/13/2026 (Estimated)THTarget Hospitality-$37.12M-$0.44N/A25.68N/A-13.47%-11.11%-8.13%8/6/2026 (Estimated)Latest SVA, TH, BCT, and IPA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026THTarget Hospitality-$0.11-$0.13-$0.02-$0.13$73.20 million$72.78 million3/11/2026Q4 2025THTarget Hospitality-$0.10-$0.15-$0.05-$0.15$85.20 million$89.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTBriaCell Therapeutics0.05129.63128.68IPAImmunoPrecise Antibodies0.492.081.85SVASinovac BiotechN/AN/AN/ATHTarget Hospitality0.080.850.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTBriaCell TherapeuticsN/AIPAImmunoPrecise Antibodies6.70%SVASinovac BiotechN/ATHTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipBCTBriaCell TherapeuticsN/AIPAImmunoPrecise Antibodies6.83%SVASinovac Biotech12.79%THTarget Hospitality3.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTBriaCell Therapeutics515.91 millionN/ANot OptionableIPAImmunoPrecise Antibodies8046.15 million43.00 millionNot OptionableSVASinovac Biotech2,64399.64 million86.89 millionOptionableTHTarget Hospitality820100.16 million96.36 millionNot OptionableSVA, TH, BCT, and IPA HeadlinesRecent News About These CompaniesTarget Hospitality Corp. (NASDAQ:TH) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 6, 2026 | americanbankingnews.comTarget Hospitality Is Aiming At The Right Growth Path, But Fully PricedJune 5, 2026 | seekingalpha.comTarget Hospitality Announces Closing of Secondary Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesMay 29, 2026 | prnewswire.comTarget Hospitality Corp (TH) Shares Fall 6.1% -- GF Value Says Still OvervaluedMay 28, 2026 | gurufocus.comTarget Hospitality Announces Pricing of Secondary OfferingMay 28, 2026 | prnewswire.comTarget Hospitality Announces Launch of Secondary OfferingMay 27, 2026 | prnewswire.comConsumer discretionary - travel and vacation providers stocks Q1 highlights: Target Hospitality (NASDAQ:TH)May 20, 2026 | msn.comTarget Hospitality, Tapestry, and Movado Shares Are Falling, What You Need To KnowMay 16, 2026 | finance.yahoo.comTarget Hospitality Faces Growth Constraints Amid Capital Access and Funding ChallengesMay 14, 2026 | theglobeandmail.comTarget Hospitality (TH) price target increased by 28.79% to 21.68May 14, 2026 | msn.comTarget Hospitality Corp.May 14, 2026 | edition.cnn.comA Look At Target Hospitality (TH) Valuation After Strong Multi Year Share Price GainsMay 13, 2026 | finance.yahoo.comWhy are Target Hospitality (TH) shares soaring today?May 12, 2026 | msn.comTarget Hospitality (NASDAQ:TH) reports sales below analyst estimates in Q1 CY2026 earnings, but stock soars 6.2%May 12, 2026 | msn.comTarget Hospitality Corp. (TH) Q1 2026 Earnings Call TranscriptMay 11, 2026 | seekingalpha.comHere's What Key Metrics Tell Us About Target Hospitality (TH) Q1 EarningsMay 11, 2026 | zacks.comTarget Hospitality (TH) Reports Q1 Loss, Lags Revenue EstimatesMay 11, 2026 | zacks.comTarget Hospitality Announces First Quarter 2026 Results Highlighting Sustained Momentum and Continued Execution on Strategic TransformationMay 11, 2026 | prnewswire.comWhat to expect from Target Hospitality’s (TH) Q1 earningsMay 10, 2026 | msn.comTarget Hospitality Corp (TH) Q1 2026 Earnings Report Preview: What To Look ForMay 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026SVA, TH, BCT, and IPA Company DescriptionsBriaCell Therapeutics CVE:BCTC$10.60 -0.42 (-3.81%) As of 12/30/2021BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.ImmunoPrecise Antibodies NASDAQ:IPAImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Sinovac Biotech NASDAQ:SVA$6.47 0.00 (0.00%) As of 06/9/2026Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.Target Hospitality NASDAQ:TH$17.20 +0.17 (+0.97%) As of 10:32 AM Eastern This is a fair market value price provided by Massive. Learn more.Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Biggest Opportunity From SpaceX’s IPO May Surprise You Chewy’s Growth Engine Is Stronger Than the Market Thinks Everpure: AI Storage Uncertainty Overshadows Breakneck Growth As Shares Fall, Analyst Are Boosting their Broadcom Price Targets This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason FuelCell Energy Just Got a Wake-Up Call From Wall Street Intel Is the Market's Most Mispriced AI Hedge Palantir's AIPCon Shows Why Customers Are Fueling the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
